BLISOVI FE 1.5/30 - norethindrone acetate and ethinyl estradio Lupin Pharmaceuticals, Inc.

Bisovištrade; Fe 1.5/30 (noretihindrone acetate and ethinyl estradiol tablets USP and ferrous hustradiol acetate and thinyl estradiol tablets USP and ferrous "Ferrous Fumarate Tablets are not USP for dissolution ovi''' Fe 1.5/30

Each pink tablet contains 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. Each brown tablet contains 75 mg ferrous fumarate.

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

Caparette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of Caparettes smoked. For this reason, COCs, including Blowler 1.5(3), are contraindicated in women with are over 35 years of age and smoke (see CONTRAMIDCATIONS and WARNINGS).

DESCRIPTION

Bisov Fe 1,570 b progestogen-estrogen combination. Bisov Fe 1,570 provides a continuous dosage regimen consisting of 21 oral contraceptive tablest and seven ferrous fumarate tablests. The ferrous fumarate tablest are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any the negative purpose.

International and use that the diputed approximation of the diputed parameters of the diputed approximation of the diputed approxim Each brown placebo tablet contains ferrous fumarate, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate, and sucrose.

Norethindrone Acetate
$$C_{2pH_{20}Q_5}$$
 $C_{2pH_{20}Q_5}$ $C_{2pH_{20}Q_5}$ Molecular

Molecular Weight: 340,46

Ethinyl Estradio

 $c_{20}H_{20}c_{2}$

Molecular Weight: 296,40

The ferrous fumarate tablets do not serve any therapeutic purpose.

CLINICAL PHARMACOLOGY

Combination contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which in crease the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).

Pharmacokinetics

Pharmacokinetics The pharmacokinetics of Bisovi Fe 1.5/30 have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature.

Absorption

Assorption
Assorption
Norethindrone actesta appears to be completely and rapidly deacetylated to
notethindrone after oral administrations, since the disposition of notethindrone actestate is
exceeded as the exceeded as the

Distribution

Distribution Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg (1 to 3). Plasma protein binding of both steroids is extensive (greater than 95%); norethindrone bindis to both abumin and sex hormone binding globulin, whereas ethinyl estradiol binds only to abumin (4).

Metabolism

Preclabolism Norehindrone undergoes extensive biotransformation, primarily via reduction, followed by suffare and guicuronide comparison. The majority of metabolites in the circulation are around in ornerhindrone actetate is intrabiciably converted to ethnyl estratioal. Ethnyl estratioal is also extensively metabolized, both by oxidation and by conjugation with suffare and guicuronide. Suffares are the major circulation conjugates of their yestration and guicuronides predominate in urities. The primary oxidate metabolite is 2-hydroxy ethnyl estratioal formed by the CMP34 alsoform of cytonicme P450. Part of the Frst-pass metabolism of ethnyl stratabils beleved to occur in gastrotitestinal mucosa. Ethnyl estration (6).

Excretion

Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites (5,6). Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg) (1-3).

Special Population Race

The effect of race on the disposition of Blisovi Fe 1.5/30 has not been evaluated.

Renal Insufficiency

kenai insurricency The effect of renal disease on the disposition of Bloovi Fe 1.5/30 has not been evaluated. In premenopausal women with chronic renal failure undergoing performed disys's who normalizes and the effect of the normalized compared to concentrations were higher and normaline distribution concentrations, were unchanged compared to concentrations in premenopausal women with normal renal function.

with normal rena function. **Hepatic Insufficiency** The effect of hepatic disease on the disposition of norethindrone acetate and ethinyl estradial tables has not been evaluated. However, estimyl estradial and norethindrone may be poorly metabolized in patients with impaired liver function.

Drug-Drug Interactions Numerous drug-drug interactions have been reported for oral contraceptives. A summary of these is found under PRECAUTIONS, Drug Interactions.

INDICATIONS AND USAGE

Blisovi Fe 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. ora contraceptives are initial derived. The factor of the second second

TABLE I: LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD

Method	Lowest Expected*	Typical
No contraception)	(85)	(85)
Oral contraceptives		3
Combined	0.1	N/A [‡]
Progestin only	0.5	N/A‡
Diaphragm with spermicidal cream or elly	6	20
Spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film)	6	26
/aginal Sponge		
Nulliparous	9	20
Parous	20	40
mplant	0.05	0.05
njection:depot medroxyprogesterone	0.3	0.3
UD		
Progesterone T	1.5	2.0
Copper T 380A	0.6	0.8
LNg 20	0.1	0.1
Condom without spermicides		
Female	5	21
Male	3	14
Cervical Cap with spermicidal Cream of elly		
Nulliparous	9	20
Parous	26	40
Periodic abstinence (all methods)	1 to 9	25
Vithdrawal	4	19
Female sterilization	0.5	0.5
Male sterilization	0.10	0.15

autnors' best guess of the percentage of women expected to expenence and dental pregnancy among couples who initiate a method (not necessarily for the first) and who use it consistently and correctly during the first year if they do not stop for

Oral contraceptives are contraindicated in women who currently have the following

- concerns: 1 Thrombophiebiks or thromboenboik disorders A past history of deep ven thrombophiebiks or thromboenboik disorders Cerderal vascular or coronary artery disease. Cerkeral vascular disease of the transple hommoe sensible Cerkerna of the endometrum or other known or suspected estrogen-dependent neoplasia

- neopissi Undiagnosed abnormal genital bleeding Chokstatic juundlee of pregnancy or juundlee with prior pill use Hegalic adenomas or carcinomas Are receiving Hegatitis C ang combinations containing ombiaswityParteeNitomavi, with or without diseadowir, due to the potential for ALT elevations (see WARNINGS, NSK OF LUKE REXTME ELEVATIONS WITH CONCOMPTIAT WEAPTITIS C FRAMEWENT).

WARNINGS

The use of valic contranceptives is associated with increased risks of several serious conditions including mycardial interioria, httpm/bendioms, strake, hepetic neoplasis, and galibadder diseste, athough the risk of serious morbidity or mortality is very small in heathy women wholu underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hypertelyidemias, obesity, and diabetes.


oners prescribing oral contraceptives should be familiar with the following ition relating to these risks. The information contained in this package insert is principally based on studies are out in patients who used on al contraceptives with higher formulations of estrogens progestogens than those in common use today. The effect of long-term use of the contraceptives with ower formulations of both estrogens and progestogens trans-

be determined. Throughout this labeling, explemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide an ensure of the relative RK of a disease. In annely, a ratio of the relative relative studies of the studies of the studies of the studies relative relative studies of the studies of the studies of the studies relative relative studies of the studies of the studies of the studies relative relative studies of the studies of the studies of the studies relative relative studies of the studies of the studies of the studies of the incidence of disease between or raid contraceptive users and nonusers. The attributable (adapted from NetGenerous B and 9 with the authors permission). For further information, the relative is cont one permission, its of the population thromation, the relative is referrent to a studie on permission.

1. Thromboembolic Disorders and Other Vascular Problems

Myocardial Infarction

a. Myocardial Infarction
An Increase disk of myocardial Infarction has been attributed to oral contraceptive use. This risk is primarly in smokers or women with other underlying risk factors for coronary attrey losses such as hypotension, hypercholestrevelmi, morotid obesity, and diabetes. The relative risk of heart attack for current oral contraceptive users has been estimated to be two to six (c1-61). The risk is very low under the age of 30.
Smoking in combination with oral contraceptive use has been shown to contribute substartially to the incidence of myocardial infarctions in women in ther mini-thrites or older with smoking accounting for the majority of excess cases (17). Mortally rates moders our the age of 35 and non-smokers over the age of 40 (Table II) among women who use oral contraceptives.



Adapted from P.M. Layde and V. Beral, Reference 18

--uspects uron r.m. Lappe and V. Berd, Reference 18 Oral contracepters may compound the effects of weld-known risk factors, such as hypertension, diabetes, hyperiodemiae, age and obesity (19). In particular, some projestogens may create a state of hyperinsultimic 70-74). Oral contraceptives be en shown to forcease block pressure annog users face scolor 9 # MARMINGSJ. density of the state of the state of hyperinsultimic 70-74). Oral contraceptives the end of the state of the stat ral contrac k factors.

Thromboembolism

An increased risk of thromboenboik and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to non-users to be 3 for the first peloxide of supericitivit evenus thrombosis, 4 to 11 for deep veh thrombosis or pulmonary emotism, and 15 to 6 for women with predisposing conditions for venues thrombosites (9.10,25.30). Cohort studies have shown the relative risk to be somewhat budies, about 3 for new cases and about 4.5 for new cases requiring hospitalization (31). The risk of thromboembolic disease due to oral contraceptives is not related to length of use and disappears after pill use is stopped (8).

disappears after pli use is stopped (8). A two: to four-foul increase in relative risk of postoperative thromboenholic complications has been reported with the use of oral contraceptives (15.32). The relative risk of venous thromboss in women who have predisposing conditions is twice that of women without such medical conditions (15.32). If feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after dectarties urgery of a type associated with an increase in risk of thromboenholism and following invincrised risk of thromboenholism, oral contraceptives should be started on earlier than four to six weeks after delevery in women who elect not to breastfeed.

Cerebrovascular Disease

Conclustration in the set of t

strokes (33-35). In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension (36). The relative risk contractive for the stroke of the stroke of the stroke of the stroke of the who used or al contractive, 18 for normotensive users, and 25.7 for users with severe hypertension (36). The attributable risk also granter in older women (9).

Dose-Related Risk of Vascular Disease from Oral Contraceptives a. Does-Related fisk of Vascular Disease from Oral Contraceptives A poshes association has been observed between the amount of estrogen and progetogen in oral contraceptives and the risk of vascular disease (37-39). A decline in serum high-density lipoprotens (HCL) has been reported with many progestational agents (20-22). A decline in serum high-density lipoprotens has been associated with an increased incidence of schemic hater likeses. Because settingens horases HDL cholesterol, the net effect of an oral contraceptive digensits on a balance achieved the amount and activity of both hormones should be considered in the choice of an oral contraceptive. The mount and activity of both hormones should be considered in the minimizing negressite in the setting.

choice of an oral contraceptive. Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular oral contraceptive, the dosage regimen prescribed should be one which contains the beat amount of estrogen and progestogen that is compatible with the needs of the individual patient. New acceptors of oral contraceptive produces satisfactory results for the patient.
e. Persistence of Risk of Vascular Disease

e. Persistence of Risk of Vascular Disease There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United States, the risk of developing myocrafial inflaction after discontinuogo rai contraceptives persists for at less 19 years for women 40 to 49 years who had used oral contraceptives for 5 or more years, but this increased risk was not demonstrated in other age groups (14). In another study in Greet Britan, the risk of developing cerebrowaccular disease persisted for at least 6 units (10). However, both studies were performed with oral contraceptive formulations containing 50 mcg or higher of estrogens.

2. Estimates of Mortality from Contraceptive Use

2. Estimates of Mortality from Contraceptive Use One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table III). These estimates include the combined risk of data associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has to specific benefits and risk. This study conclude that under who do not smoke, mortality associated with all methods of thirts control is low and object who do not smoke. Mortality associated with all methods of thirts control is low and both of the goal with all thirds. The observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970s but not reported and 11933 (31). However, current chinate practice molves the use of both oral protoce channels haves channels in contract but haves the use of both oral protoce channels haves channel channels and the based on the protoce channels haves channel and the contraception of the based on the protoce channel haves channel and the channel of a channel have the both oral protoce channels and the based on the substance of the based on the protoce channels and the channel of cannels have the based on the protoce channel have protoce on the based on the substance of the substance of the substance of the based on the substance of the based on the based on the substance of the based on the based of the substance of the based on the based

use to women who do not have the various risk factors listed in this blefting. Because of these changes in practice and Jaio. Decause of some hinded new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives and contraceptives and nonfatal vascular disease. Disstet Gynecol 1985;56:1-4 and Potter [6]. Hershel], Varier AM. Mortally among oral contraceptive users. Distet Gynecol 1985; [6]. Hershel], Varier AM. Mortally among oral contraceptive users. Obstet Gynecol 1985; [6]. Hershel], Varier AM. Mortally among oral contraceptive users. Distet Gynecol 1985; [6]. Hershel], Varier AM. Mortally among oral contraceptive users. Distet Gynecol to review the tippic in 1989. The Committee concluded that athrough cardiovascular disease risks may be increased with our contraceptive user attrace and the healthy non-smiching women (even with the newer low-dose formulations), there are greater potential health risk associated with the previous of an other action of the athrough the attrace surged and method approximates which may be necessary if such women do not have barden barden barden barden action action of the barden barden

access to enecute and acceptable means on contraception. Therefore, the Committee recommended that the benefits of oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks. Of course, olde women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective.

TABLE III: ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE

Method of control 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44

No fertility control methods	7.0	7.4	9.1	14.8	25.7	28.2
Oral contraceptives non-smoker [†]	0.3	0.5	0.9	1.9	13.8	31.6
Oral contraceptives smoker [†]	2.2	3.4	6.6	13.5	51.1	117.2
IUD [†]	0.8	0.8	1.0	1.0	1.4	1.4
Condom*	1.1	1.6	0.7	0.2	0.3	0.4
Diaphragm/spermicide*	1.9	1.2	1.2	1.3	2.2	2.8
Periodic abstinence*	25	1.6	1.6	17	2.9	3.6

3. Malignant Neoplasms

Breast Cance

Blisovi Fe 1.5/30 is contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive (see CONTRAINDICATIONS) Exidenticity y tutiles have not found a concisionar association between insis of combined and contraceptions (COC) and busine concer risk. Subtisk on not shown association between ever (current or past) use of COCs and risks of breast cancer. However, some subtisks report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use (see ADVERSE ERECTIONS, Postmarkeng Experimence).

Cervical Cancer Lerva Lancer Some studies suggest that oral contraceptive use has been associated with an increa in the risk of cervical intragelihelial neoplasia in some populations of women (42-45). However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.

4. Hepatic Neoplasia

4. Nepatic Neoplasia
Bengin hipszis categorius are associated with oral contraceptive use, athough the incidence of bengin pumors is rare in the United States. Indirect calculations have estimated the attrivulation risk to be in terange of 3.3 cases(0.00,000 for uses, a risk that increases after four or more years of use (48), hupture of and bengin, hepatic Statis from that hin have haven an increased risk of developing hepatical calculations (40-51) in bong term ignitizes than a syntaxy in a statistical carcinoma (40-51) in bong term ignitizes than a syntaxy is and in the attributable risk the excess in collection of were cancers in oral contraceptive users.

5. Risk of Liver Enzyme Elevations with Concomitant Henatitis C Treatment 3. KBA of LAPP Enzyme Levations with Concomitant Hepatitis L Treatment During chick at larks with the Hepatitis C combination drug regrems that contrains than 5 burns chick at larks with the Hepatitis C combination drug regrems that contrains than 5 times the upper limit of normal (ULM), including some cases greater than 20 times the ULM, were significantly more frequent in women using drug hepatitistication of the medications such as COSC. Discontinue Bioch Pet 1.500 prior to starting therapy with disabutiv (see Contraindications (L)). Norethindring exclusion action and the restarted approximately 2 weeks following completion of treatment with the combination drug regress.

6. Ocular Lesions

There have been clinical case reports of rethial thrombosis associated with the use oral contraceptives. Oral contraceptives should be discontinued if there is unexplain partial or complete loss of vision, conset of proptoss or diplopis, papiledema; or reti vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately.

The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion.

to treat threatened or habitual abortion. It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before conthuing or al contra-eptive use. If the patient has not adhreed to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral contraceptive use should be discontinued if pregnancy is confirmed.

8. Gallbladder Disease

a disadvance is because in the second of the second of

9. Carbohydrate and Lipid Metabolic Effects

9. Carbohydrate and Lipd Metabolic Effects
Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users (23). Oral contraceptives containing greater than 75 mcg of estrogens cause less physical between obset of estrogen cause less glucose. In this diffect varying with different progestational agents (23, 63). However, in the non-dibletic worman, oral contraceptives appear to have no effect on facting bold glucose carefully observed while taking oral contraceptives. A small proportion of wormen will have persisten thy perturphysical base in the other of a discussed earlier (see WARWROS; 1a, and 1a), changes in serum trighcendes and lipoprotein levels have been reported in oral contraceptive users.

10. Elevated Blood Pressure

10. Elevated Blood Pressure An increase in blood pressure has been reported in women taking oral contraceptives (increase in blood pressure has been reported in women taking oral contraceptives (increase) and increase the blood contraceptive (increase) and increasing subsequent randomized tribs have shown that the incidence of hypertension increases with increasing concentrations of progestogens. Women with a history of hypertension or hypertension-related diseases or renal desaus (if) should be encouraged to use another method of contraception. If women elect to (if) should be encouraged to use another method of contraception. If women elect blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping or al contraceptives (66), and there is no difference in the occurrence of hypertension among ever and never user: (65, nf).

11. Headache

The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause.

12. Bleeding Irregularities

.c. oeeding Irregularities Breaktivough beeding and spotting are sometimes encountered in patients on ord strong the source of the source o

Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent.

13. Hereditary Angioedema

In women with hereditary angloedema, exogenous estrogens may induce or exacerbate symptoms of angloedema.

14. Depression

Carefully observe women with a history of depression and discontinue Blisovi Fe 1.5/30 if depression recurs to a serious degree.

PRECAUTIONS 1. Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted infections.

2. Physical Examination and Follow-Up

2. Physical Examination and Follow-Up It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred und after miniation of oral contraceptives if requested by the woman and judged appropriate by the clinican. The physical examination should include special reference to blood pressure, pressts, abdomen and pelkic organs, including cervical cytobagy, and relevant biboratory tests. In case of undiagnosed, persistent or ucurrent autometu lagnal belefing, appropriate measures should be conducted to rule breast indules should be monitored with particular case.

3. Lipid Disorders

Women who are being treated for hyperlipidemia should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult.

4. Liver Function

If jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with impaired liver function.

5. Fluid Retention

Oral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention.

6 Contact Lenses

Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist. 7. Drug Interactions

Effects of Other Drugs on Oral Contraceptives (69)

Rifampin: Metabolism of both norethindrone and ethinyl estradiol is increased by rifampin. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin.

carbamazepine, have been shown to increase the metabolism of ethinyl estradiol and/or norethindrone, which could result in a reduction in contraceptive effectiveness.

Trojitazore: A minin tous traus tra reduction in contraceptive effectiveness. Trojitazore: A mininistration of ropitazone with an oral contraceptive effectiveness. Antibiotics: Pregnancy while taking oral contraceptive effectiveness. Antibiotics: Pregnancy while taking oral contraceptives thas been reported when the oral contraceptive effective with antimicrobia such as any picit, tetracycline oral contract policy effectives. The such as the such as any picit, tetracycline such as the such as the such as the such as any picit, tetracycline constant effect of antibiotics (other than rfampin) on plasma concentrations of synthetic stretion.

Atorvastatin: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%, respectively.

respectively. Concomitant Use with HCV Combination Therapy - Liver Enzyme Elevation: Co-admitistration of norethindrone acetate and ethinyl estradio with HCV drug combinations containing ombasively hargereviritionasiv, with or without dasabuvir is contraindicated due to potential for ALT elevators. Gere WARNINGS, RISK OF LIVER LEVITHE ELEVATIONS WITH CONCENTIANT HEARTIST CHEATINETT, Co-administration of norethindrone acetate and ethinyl estradid and glecapreviripheretas is not recommended due to potential for ALT elevators.

s not recommended use of potentiation Act Texabolis. Other: Ascord acid and actemationphen may increase plasma ethinyi estradiol concentrations, possibly by inhibition of conjugation. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding has been suggested with phenylbutazone.

Effects of Oral Contraceptives on Other Drugs

Effects of Varia Contractives on Uniter Jung Oral contraceptive combinations container Jung of other compounds. Increased pissma concentrations of cyclosporine predinsione, and theophythen sub deen reported with concomitant administration of oral contraceptives, in addition, or all contraceptives may induce the conjugation of other clearnce of therapean, sakyle accil unorphile, and coffortic call have been noted when these drugs were administered with oral contraceptives.

8. Interactions with Laboratory Tests

Certain endocrine and liver function tests and blood components may be affected by oral contraceptives:

or ar contraceptives: a. Increased norepinephrine-induced platekt aggregability. b. Increased norepinephrine-induced platekt aggregability. b. Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by proten-bound odder (FB), it gly column of by radiommunoassay. Free Tj resin uptake is decreased, reflecting the elevated TBG, free T_a concentration is unablered. Other binding proteins may be elevated in serum.

- Sex-binding globulins are increased and result in elevated levels of total circulating steroids and corticoids; however, free or biologically active levels remain unchanged
- e. Triglycerides may be increased. f. Glucose tolerance may be decreased.
- g. Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives.

9. Carcinogenesis

See WARNINGS section.

10. Pregnancy Discontinue Blisovi Fe 1.5/30 if pregnancy occurs because there is no reason to use COCs in pregnancy. See WARNINGS section.

11. Lactation

The answerster of oral contraceptive steroids have been identified in human mile, and a forw idence affection to the dist have been reported in Lucitariji junicia and breast enlargement. In addition, oral contraceptives, given in the postpartum period may interfere with laction by decreasing the quantity and quality of breast mile. If possible, the nursing mother should be advised not to use or al contraceptives but to use other forms of contraception und is he has completely averaged the child.

12. Pediatric Use

Safety and efficacy of norethindrone acetate and ethinyl estradiol have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated.

PATIENT COUNSELING INFORMATION

r-ILTI-LOUNSELING INFORMATION Advice the patter to read the TG-Asproved patient backing (PATIENT PACKAGE INSERT BRIEF SUMMARY and DETALED PATIENT PACKAGE INSERT). Counsel patients that cigaretise smoking increases the risk of serious cardiovaculier venets from COC use, and that women who are over 35 years oil and smoke should not use COCs (see Counse) patients that the increased risk of venous thromboemboken compared to nonuess of CHCs is greatest after initially starting a CHC or restarting (following a 4-week or

- week or greater immution is instake) the same or a different CHC (see WARNINGS). Or greater immution is instake) the same or a different CHC (see WARNINGS) with the sexually transmitted infections. Counsel patients to take one table daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed (see DOSAGE AND ADMINISTRATION).
- Instruct patents what to do in the event plis are missed (see DDSAGE AND Control patents) are a back-ing or alternative method of contraception when enzyme induces are used with COCs (see PRECAUTIONS). Counsel patents who are brastfereding or who desire to brastfered that COCs may reduce breast milk production. This is essi likely to occur if breastfereding is well established deer PRECAUTIONS). The stabilished deer PRECAUTIONS (see PRECAUTIONS). The stabilished deer PRECAUTIONS) is a stabilished to the stabilished deer precision of the stabilished deer precision and vector that are obtailed with symptoms of precision stabilished deer precision may decure. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women should contact their healthcare provider if depression nat recourt. Women sho

ADVERSE REACTIONS

ADVERSE FLACTIONS
An Increased risk of the following serious adverse reactions has been associated with
the use of oral contraceptives *(see WARNINGS section):*Thrombophiebis
Arterial thromboembolism
Pulyinoary enholism
Ceretrial thromboembolism
Ceretrial thromboembolism
Ceretrial thromboembolism
Occelerate alternormage
Ceretrial thromboembolism
Occelerate alternormage
Ceretrial thromboembolism
Occelerate alternormage
Ceretrial thromboembolism
Occelerate alternormage
Occelerate al

Post Marketing Experience Five studies that compared breast cancer risk between ever-users (current or past use of COCs and new-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 to 1.12 (Figure 1) (70-74).

(4). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 1) (70, 73, 75). One of these studies reported in association between breast cancer risk and COC user the other two studies found an increased relative risk of 1.31 with current or recent use. Both of these studies found an increase risk of 0 association between the current use use to henge relative the other two and the comparison of the other two approximately 1.4 with more than 8 to 10 years of COC use to approximately 1.4 with more than 8 to 10 years of COC use. FIGURE 1: RELEVANT STUDIES OF RISK OF BREAST CANCER WITH COMBINED DAAL CONTACCEPTIVES

Ever COC vs. Never COC Use NICHD Women's Care Study, Marchbanks PA. 2002		OR: 0.90 (0.80, 1.00)
French E3N cohort Study, Dameaux V. 2005	····	RR:0.91 (0.81, 1.03)
Shanghai Worren's Health Stady, Dorjgochoo T. 2009	· · · · ·	HR: 1.05 (0.84, 1.31)
The Nurses' Health Study II, Hunter DJ. 2010	• • • •	RR: 1.12 (0.95, 1.33)
Dxford Family Planning Study, Vessey M. 2013	•••	RR: 1.00 (0.90, 1.10)

-1.50	-1.00	-0.50	0.00	0.50	1.00	1.50	2.00	
Danish Sex Hi	ormone Register:	Study, Morch LS.	2017			•	RR:1.19(1.13,	1.26)
	isalth Stady II, Hu				•	• •	RR: 1.33 (1.03,	1.73)
		la rohbanks PA. 21	102			•	OR: 1.00 (0.80,	1.30)
	sse vs. Never-Us							
Oxford Family	Planning Study,	Vessey M. 2013			-		RR: 1.00 (0.90,	1.10)
The Nurses' H	lealth Stady II, Hu	nter OJ. 2010				-	RR: 1.12 (0.95,	
Shanghai Wor	men's Health Stat	y, Dorygecheo 1.	2009		-	-	HIK: 1.05 (0.84,	1.31)

Effect Estimate Effect Estimate are females that never used COCs.

There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed: Mesenteric thrombosis • Retinal thrombosis

A retrait unomoso
 A retrait unomoso
 The following advected to be drug-related:
 The following advected to be drug-related:
 Vomning
 Gastroinestnial symptoms (such as abdominal cramps and bibating)
 Spatting
 Spatting
 Spatting
 Amenormae

- Amenormea Temporary infertility after discontinuation of treatment Edema

- Edema Melasma which may persist Breast changes: tenderness, enlargement, secretion Change in weight (increase or decrease) Change in cervical erosion and secretion Diminution in lactation when given immediately postpartum Cholestatic jaundice

- Migraine
 Rash (allergic)
 Depression

Reduced tolerance to carbohydrates

Vaginal candidiasis Change in corneal curvature (steepening) Intolerance to contact lenses

Intolerance to contact tenses Intolerance to contact tenses Intolerance to contact tenses Intolerance tenses reactions have been reported in users of oral contraceptives and the association has been nether confirmed nor refuted. Pre-mestrual syndrome Cataracts Charges hapetite Charges hapetite Charges hapetite Nervourses Dezines Headach Nervourses Dezines Pre-mestrual physical syndrome Erythema nodosum Hemoritagic eruption Vagnitg Impaired renal function Henolytic urrence syndrome Henolytic urrence syndrome Henolytic urrence syndrome Budd-Charl syndrome Budd-Charl syndrome

- Changes in libido
 Colitis

Seribus II effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.

NON-CONTRACEPTIVE HEALTH BENEFITS

The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol (76-81).

mg of mestranol (/o-o1,) Effects on menses: • Increased menstrual cycle regularity • Decreased blood loss and decreased incidence of iron deficiency anemia • Decreased incidence of dysmenorrhea

Decreased incluence of dysmenormea

Effects related to inhibition of ovulation:
 Decreased incluence of functional ovarian cysts
 Decreased incluence of ectopic pregnancies

Effects from long-term use: • Decreased incidence of fibroadenomas and fibrocystic disease of the breast • Decreased incidence of actue perkic inflammatory disease • Decreased incidence of endometrial cancer • Decreased incidence of ovarian cancer

DOSAGE AND ADMINISTRATION

DOSAGE AND ADMINISTRATION The bitter has been deligned to make oral contrarestite desing as day and as the days of the week appearing on the arranged in four row of areas tables each, with the days of the week appearing on the bitter above the fact row or tables. Note: Each bitter has been preprinted with the days of the week, starting with Sunday. To facilitate 3 sunday Start regimes. Su different day bitters track bitters than or tables accommodate a Dayl 1 Start regimes. If the patient is using the Dayl 1 Start regimes, she the preprinted days.

Important: The patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle when utilizing the Sunday-

The possibility of ovulation and conception prior to initiation of use should be considered

Dosage and Administration for 28-Day Dosage Regimen

To achieve maximum contraceptive effectiveness, Blisovi Fe 1.5/30 should be taken exactly as directed and at intervals not exceeding 24 hours.

exactly as directed and at intervals not exceeding 24 hours. BisovF = 1.5/20 provides a continuous administration regimen consisting of 21 pink tables of BisovF = 1.5/20 and 7 bown non-hormone containing tables of forous fumarate. The ferrous fumarate tables are present to facilitate ease of drug administration via 28-day regimen and do not serve any therapeutic purpose. There is no need for the patient to count days between cycles because there are no "off-tablet days."

days. Sunday-Start Regiment: The patient bejot taken to the first phyticable from the top row of the bister (labeled sunday) on the first Sunday after mestrual flow begins. When mentrual flow begins on Sunday, the first phyticable is taken on the same day. The patient takes one phyticable day for 21 days. The last phyticable is the bister will be patient takes one phyticable days for 21 days. The last phyticable is the bister will be patient takes one phyticable days for 23 days. Unclusion completion of this first course of tables, the patient begins a second course of 28-tables, whon't iterruption, the rest day (Standys), tatting with the solidary phytic tables the top for x. Aftering to the brown tablet day for seven days, the patient will start all subsequent cycles on a Sunday.

Sunday. 2. Day J Start Regimen: The first day of menstrual flow is Day 1. The patient places the self-adhesive day label strip that corresponds to her starting day over the preprinted days on the blaces. The start starking one physical table day, beginning with the first phic tablet in the top row. After the last physical tablet day, beginning with the subscience t-cycles, the patient begins are well tablet (at the end of the third row) subscience t-cycles, the patient begins are well tablet regime on the eighth day after taking her inst phic tablet, again starting with the first tablet in the top row after placing regimen of 21 phic tablets and 7 brown tablets, the patient will start all subsequent cycles on the same day of the weeks at the first crasses.

Tablets should be taken regularly with a meal or at bedtime. It should be stressed that efficacy of medication depends on strict adherence to the dosage schedule.

Special Notes on Administration

Appendix to the source of the

Learning Jame Labels, container medication window metrupuon. If the patient forgets to take one or more **pink** tablets, the following is suggested: **One** tablet is missed • take tablet as soon as remembered • take next tablet at the regular time

Two consecutive tablets are missed (week 1 or week 2) • take twotablets as soon as remembered • take twotablets the next day • use another birth control method for seven days following the missed tablets Two consecutive tablets are missed (week 3)

The unisecular causes are imased (week 3) Sunday-Start Regimen: take onetablet daily until Sunday d discart remaining tablets • start new pack of tablets immediately (Sunday) • start new pack of tablets immediately (Sunday)

Day-1 Start Regimen: • discard remaining tablets • start new pack of tablets that same day • use another birth control method for seven days following the missed tablets Three (or more) consecutive tablets are missed

Intere (or Indie): Collisionale balance are missed Sunday-Start Regimen: • Take onetablek daily until Sunday discard remaining tablets • start new pack of tablets immediately (Sunday) • start new pack of tablets immediately (Sunday) Day-1 Start Regimen: • discard remaining tablets • start new pack of tablets that same day • use another birth control method for seven days following the missed tablets

use ensures our control method for seven days following the missel tablets the possibility of woldsine occurring increases with each successive day that is choluded pink tablets are missed. While there is little kilohood of ovulation occurring if only one pink tablets makes, the possibility of spotting or bleeding is in creased. This is particularly likely to occur if two or more consecutive pink tablets makes four, those brown tablets that were missed are discarded and one brown tablets in werk (our, those brown tablets that were missed are discarded and one brown tablet is taken each day, until then pack is empty. A back-up birth control method is not required during this time. A new pack or tablets should be started no later than the eighth day after the last pink tablet was taken.

was taken. In the rare case of bleeding which resembles menstruation, the patient should be advised to discontinue medication and then begin taking tablets from a new bilster the next Sunday or the first ady (Day-1), depending on her regime. Persitent bi which is not controlled by this method indicates the need for reseamination of the patient, at which time nonfunctional causes should be considered.

Use of Oral Contraceptives in the Event of a Missed Menstrual Period: If the patient has not adhered to the prescribed dosage regimen, the possibility of pregnancy should be considered after the first missed period and oral contraceptives should be withheld until pregnancy has been ruled out.

If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen.

After several months on treatment, bleeding may be reduced to a point of virtual absence. This reduced flow may occur as a result of medication, in which event it is not indicative of pregnancy.

HOW SUPPLIED

Bisovi Fe 1.5/20 (28 Tablets) (norethindrone acetate and ethinyl estradiol tablets USP, 1.5 mg/0.03 mg; and ferrous fumarate tablets) are available in a bister (NDC 68180-866-71) containing 28 tablets packed in a pouch (NDC 68180-666-71). Such three pouches are packaged in a carton (NDC 68180-866-73).

pourtes are packaged in a carton (NCC 68180-86-71). Such three 21 pink colours 28 tablets, as follows: 21 pink colours (numl faft face bevelet edged tablets, each containing 1.5 mg notethindrone acetata and 0.35 mg ethnyl estradial, debossed with "LU" on one side of the service of the service deged tablets, debossed with "LU" on one side and "M22" on the other side. Each brown tablet contains 75 mg ferrous fumarate. The forous fumarate tablets are present or facilitate ease of drug addressing brown.

Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]

- Back RJ, SPC (17PF): Exactisizing permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].
 BEREENCEE
 In Back RJ, Breckenridge AM, Crawford FE, McIver M, Orme ME, Rowe PH and Smith E: Endeck of noterhitrone in women II. Single-dock selects. Clin Pharmacol The 1378; 21, 4446 453.
 In Charles M, Santon M, Santo M, Santon J, Santon M, Santon J, Santon M, Santon M, Santon J, Santon M, Santon J, San
- Wanit Y., L. Yasaniti Y., Yasani Y.

- Winn, V., and I. Godshand. Effects of oral contraceptives on carbodydiate metabolism. *J. Approd. Medicine*, 10 (Spupphene) 20:2497, 1398.
 Silowan, M. & K. (1999) 10 (Spupphene) 20:2497, 1399.
 Imman, W.H., and N.P. Vessey. J. Investigations of details from pulmonary, coronary, and coreteral thromosols and entroloim in women of chilo-bearing age. *Brt. Med. J.* 20:2511 (Spupphene): 90:542, 1986.
 Maguire, M.G., J. Tonscie, P.E. Stenke, P.D. Stolky, and M.S. Tockman: Increased risk of thrombosis due to oral contraceptives. A further report. *Am. J. Epidemiology*, 110(1):189, 1397.
 Maguire, M.G., J. Tonscie, P.E. Stenke, P.D. Stolky, and M.S. Tockman: Increased risk of thrombosis due to oral contraceptives. In further report. *Am. J. Epidemiology*, 110(1):188–103, 1397.
 Messey, M.P., and R. Duit Investigation of relation between use of oral contraceptives and thromboenibodic desizes. A further report. *Brt. Med. J.*, 20:5591: 651-657, 1995.
 Vessey, M.P., and R. Doll Investigation of relation between use of oral contraceptives and thromboenibodic desizes. A further report. *Brt. Med. J.*, 20:5591: 651-657, 1995.
 Vessey, M.P., and R. Doll Investigation of relation between use of oral contraceptives and thromboenibodic desizes. A further report. *Brt. Med. J.*, 20:5591: 651-657, 1995.
 Vessey, M.P., and R. Doll Investigation of relation between use of oral contraceptives and thromboenibodic desizes. A further report. *Brt. Med. J.*, 20:5591: 651-657, 1995.
 Vessey, M.P., Bolt, R. Pets, B., Johnson, and P. Wiggers Renze, Dateid and Oyn. 59(3):299-302, 1982.
 Vessey, M.R., Bolt, R. Pets, B., Johnson, and P. Wiggers Renze, Dateid and Oyn. 59(3):299-302, 1982.
 Coblaconted General Practitioners, Cital cardinal semanticity of structure of women. Using different methods.
 Coblaconted General Practitioners, Cital cardin dinteraceptives and structure several. *J. R*

- 56.
- 57.
- 58
- 59
- Madram Informance therapy and congenital heart disease. *Teratobys*, 21:225-239, Rothman KJ, D. C. Fyer, A. Goldbatt, and M. B. reisbeiger. Toogenous thormones and other drug exposures of children with congenital heart disease. *Am. J. Epidemiology*, 10:943-343, 11:391-300, 51:07810-0781, 2014, 2 60
- 61
- 62.
- 63.
- siz: 74-278, 1982. Rome Group for the Epidemiology and Prevention of Choleithiasis (GREPCO): Prevalence of galatone disease in an Italian adult female population. Am. J. Epidemiol. Storm B. B., R. T. Tamragouri, M. Linors, E. L. Lazz, S. L. West, P. D. Stoley, and J. K. Jones: Oral contraceptives and other risk factors for galabiadder disease. *Cin. Pharmacol.* 11, 1986. Wynn, V., P.W. Adams, I.F. Godstina J. Mérose, R. Niththyananthan, N.W. Oakley, and A. stord. Comparison of effects of difficient combastic 1:1047-1048. Journal of Progeterione and Progestin. Edited by C.W. Bardin, E. Milyron, P. Maudy, Javk. New York, Raven Press, pp. 393-410, 1983. Perman, J.J. A. C. Roussek Briefe D. V.W. Bardin, E. Milyron, P. Maudy, Javk. New York, Saven Press, pp. 393-410, 1983. Straneous C. C. Consels Briefer D. Contraception Study: Effect on hypertension and beingin breast disease of progestogens. J. Chronic Dis., 38837-684, 1993. Stork, I. R., and Y. Lang, L. J. K. C. Contarogatives and blood pressure. J. Adv., 237:2499-2503, 1977. 64.
- 65
- 66.
- 2503. 1977.
 C3. Laragh, A.J.: Oral contraceptive induced hypertension: Nine years later. Amer. J. Obstet Gynecol., 126:141-147, 1976.
 G8. Rancharan, S., E. Pertz, F.A. Pellegrin, and W.T. Williams: Incidence of hypertension in the Wainut Creek Contraceptive Drug Study cohort. In Pharmacobgo of Steroid Contraceptive Drugs. Edited by S. Garattini and H.W. Bernides, New York, Reven Press, pp. 277-288, 1977. (Monographs of the Maro Negri Institute for OB Back OJ, Orne NEL E. Drug Interactions. In Pharmacobgo of the contraceptive steroids, Goldzieher JW, Fotherby K (eds) Raven Press, Ltd., New York, 1994, 407-425.

- Marchanks PA, McDonakl JA, Wilson HG, et al. Orai contraceptives and the risk of breast cancer. N Engl JMed. 2002;346(26):2025-2032.
 Dumeaux V, Youmier AL, Lund E, Clavel-Chapekon F. Previous orai contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausia women. Cancer Causes Control 2005;16(5):537-544.
 Dorigochon T, Shu XO, Li HL, et al. Use of orai contraceptives, intrauterine devices and tubal settleation and cancer risk in a targe properties tubal, from 1996 to

- 2006. Int J Cancer, 2009;124(10):242-2449.
 Hunter DJ, Cokliz GA, Hankinson SE, et al. Grai contraceptive use and breast cancer: a prospective study of young women. Cancer epidemiology, biomarkers & prevention is a publication of the Printeria Accession 2010;25(10):2486-2500.
 Yessey M, Yaates D. Orai contraceptive use and cancer. Final report from the Oxford-Family Planning Association contraceptive subty. Contraceptors 2013; 88(8): Contraceptors 2013; 88(8): Contraceptors 2013; 88(8): Contraceptors 2013; 88(8): Contraceptors and Seroid Hornone Study of the Centers for Disease Control and the National Institute of Control and the Control and Beroid Hornone Study of the Centers for Disease Control and the National Institute of Coll Health and Human Development: Combination rail accession 2014; 91(2): 228-2293.
 Or, The Cancer and Seroid Hornone Study of the Centers for Disease Control and the National Institute of Coll Health and Human Development: Combination rail accession 2014; 91(2): 10(2):

Distributed by:

Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202

United States Manufactured by Lupin Limited

Pithampur (M.P.) - 454 775

INDIA

Revised: November 2023

Blisovi''' Fe 1.5/30

(norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets*) 1.5 mg/0.03 mg

*Ferrous fumarate tablets are not USP for dissolution

BRIEF SUMMARY PATIENT PACKAGE INSERT

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections.

Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (13 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongh advised not to smoke.

Oral contractedhes, aleo known as "bith control pills" or "the pill" are taken to prevent regranarcy and, when taken correctly, have a failure rate of about 1% per year when used without missing any pills. The typical failure rate of large numbers of pill users is also than 3% per year when women on missing blat are taken. To first year when the set of the set bits of the set of for the majory of women, or al contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-timateding of my cause temporary or year permanent disability. The risks associated with "encoder the set of the "encoder the set of the "encoder the set of the "encoder the set of the body for set of the se

Smoke Have high blood pressure, diabetes, high cholesterol Have or have had clotting disorders, heart attack, stroke, angina pectoris, cancer of the breast, jaundice, or malgnant or benign liver tumors.

You should not take the pill if you suspect you are pregnant or have unexplained vaginal bleeding

Diecong. Most side effects of the pill are not serious. The most common side effects are nause vomiting, bleeding between menstrual periods, weight gain, breast tenderness, and difficulty wearing contact tenses. These side effects, especially nause, vomiting, and breakthrough bleeding may subside within the first three months of use.

Interface series, increases, increases enterets, especially natures, vomiting, and breakthrough breakthrou

The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or heathcare provider i you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics, may decrease oral contraceptive effectiveness.

There may be slight increases in the risk of breast cancer, among current users of hormonal birth control jalk with longer duration of use of 8 years or more. Some studies have found an increase in the risk of developing cancer of the cervit in women taking the pit, but this finding may be related to differences in sexual behavior or other factors not related to use of the pit.

Taking the pill provides some important non-contraceptive benefits. These include less painful mestruation, less menstrual blood loss and anemia, fewer pelvic infections, and fewer cancers of the ovary and the lining of the uterus.

Tever cancers or the ovary and the lining of the Lifetis. Be sure to discuss any medical controlling you may have with your healthcare provider. Your healthcare provider will take a medical and family history and examine you before prescribing and contraceptives. The physical examination may be delayed to another time If you request it and your healthcare provider beleves that it is a good medical practice to postports. It you should be reasonined at last once a year while blands pra-practice to postports. It you should be reasonined at last once a year while blands pra-practice to postports. It you should be reasonined at last once a year while blands pra-which you should read and discuss with your healthcare provider.

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infecti genital herpes, genital warts, gonorrhea, hepatitis B and syphilis.

INSTRUCTIONS TO PATIENT

The Bisovi Fe 1.5/30 blitter has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing on the blister above the first row of tablets.

Blister:

Each blister contains 21 pink tablets and 7 brown table

Each pink tablet contains 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol

Each prior cause, contains 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. Each **brown** tablet contains 75 mg ferrous fumarate, and is intended to help you remember to take the tablets correctly. These brown tablets are not intended to have any health benefit.

DIRECTIONS

Г

ALSO FIND:

To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the bilster. Do not press on the tablet with your thumbnai, fingernail, or any other sharp object.

HOW TO TAKE THE PILL

IMPORTANT POINTS TO REMEMBER

Г

2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pils you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant.

get pregnant. 3. MMY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS. If you do have spotting or light bleeding or feels to your stomach, do not stop taking the pill. The problem will usually go away. If & doesn't go away, check with your doctor or clink. MISSING PILLS CAN LSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel all the sick to your stomach.

Could also teed attuce six to your submach. S. IF YOU HAVE VOMITING OC NURARHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your birth control pills may not work as well. Use a back-up birth control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control. 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic. BEFORE YOU START TAKING YOUR PILLS

 DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day LOOK AT YOUR PILL PACK TO SEE IF IT HAS 28 PILLS: The <u>28-Day pill pack</u> has 21 "active" pink pils (with hormones) to take for 3 weeks, followed by 1 week of reminder brown pills (without hormones).

ALSO FIND:
 Where on the pack to start taking pills,
 in what order to take the pills (follow the arrows), an
 the week numbers as shown in the following picture:

BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS

Before you start taking your pills Anytime you are not sure what to do

DAY-1 STARTERS: If your period begins on a day other than Sunday place the day label strip that starts with first day of your period. START HERE FOR BOTH Week 2 **,0,0,0,0,0,**0 10,0,0,0,0,0,0,0 10,0,0,0,0,0,0

TAKE PILLS IN THIS DIRECTION FROM LEFT TO RIGHT EACH V

For use of day labels, see WHEN TO START THE FIRST PACK OF PILLS below.

BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills.

An EXTRA, FULL PILL PACK.

WHEN TO START THE FIRST PACK OF PILLS

You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember.

DAY-1 START:

Pick the day label strip that starts with the first day of your period. (This is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins.)

Place this day label strip on the blister over the area that has the days of the week (starting with Sunday) printed on the blister.

Take the first "active" pink pill of the first pack during the first 24 hours of your rind You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period.

SUNDAY START: Take the first "active" pink pill of the first pack on the <u>Sunday after your period</u> starts, even if you are still bleeding. If your period begins on Sunday, start the pack that

<u>Use another method of birth control</u> as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control.

WHAT TO DO DURING THE MONTH

1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.

Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very oft WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS

28 pills: Start the next pack on the day after your last "reminder" pill. Do not wait any days between packs. WHAT TO DO IF YOU MISS PILLS

If you MISS 1 pink "active" pil: Take it as soon as you remember. Take the next pill at your regular time. This means u may take 2 pills in 1 day.

2. You do not need to use a back-up birth control method if you have sex If you MISS 2 pink "active" pils in a row in WEEK 1 OR WEEK 2 of your pack

If you MISS 2 pink "active" pills in a row in WEEK 10 R WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the net day. 2. Then take 1 pills day until you finkih the pack. 3. You COULD GOT PROCEMINT "you where win the 2 days after you miss pills. You MIST use another birth control method fourth as contoms of form as a back-up method of birth control undil you have save in the 2 days after you miss pills. You MIST successful pills in a row in THE 3rd WEEK:

If you are a Day-1 Starter:

THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter:

Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.

You may not have your period this month, but this is expected. However, if you
miss your period 2 months in a row, call your doctor or clinic because you might be
prennant.

3. You COULD GET PREGNANT if you have sex in the <u>7 days</u> after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a pink "active" pill every day for 7 days.

If you MISS 3 OR MORE pink "active" pills in a row (during the first 3 weeks):

If you **MIDS J OK MONE** pink: Tactive pills in a row (ouring the First 3 weeks): **If you are a Dab-3 Starter** THROW OUT the rest of the pill pack and start a new pack that same day. **If you are a Stardog Starter**. Keep taking 1 pill every day untit Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.

You may not have your period this month, but this is expected. However, if you
miss your period 2 months in a row, call your doctor or clinic because you might be
preenant.

pregnant.
3. You COULD GET PREGNANT if you have sex in the <u>7 days</u> after you miss pills.
You MUST use another birth control method (such as condoms or foam) as a back-up
method of birth control until you have taken a pink "active" pill every day for 7 days

A REMINDER FOR THOSE ON 28-DAY PACKS:

F YOU FORGET ANY OF THE 7 BROWN "REMINDER" PILLS IN WEEK 4:

THROW AWAY THE PILLS YOU MISSED. KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY.

YOU DO NOT NEED A BACK-UP METHOD. FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED:

Lise a BACK-LIP METHOD anytime you have sex

KEEP TAKING ONE PINK "ACTIVE" PILL EACH DAY until you can reach your doctor or clinic

Based on his or her assessment of your medical needs, your doctor or health care provider has prescribed this drug for you. Do not give this drug to anyone else. Keep this and all drugs out of the reach of children. Rx only

Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F). [see USP Controlled Room Temperature]. DETAILED PATIENT PACKAGE INSERT

Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted infections.

What You Should Know About Oral Contraceptives ••••••• rou anoue now About Ural Contraceptives Any woman who considers using oral contraceptives (the "birth control pills" or "the pill") should understand the benefits and risks of using this form of birth control. This kerkle will determine I you are it risk of developing any of the serious side effects of help you determine I you are it risk of developing any of the serious side effects of help you determine I you are it risk of developing any of the serious side effects of help you determine I you are it risk of the formation provided in this kerkle with him hewever, this kerkle is not a replecement for a careful doucsions between you and your heathcare provider. You should diccuss the information provided in this kerkle with him of risk both when you first stat taiking the pill and during your revisits. You should also follow your heathcare provider's advice with regard to regular check-ups while you are on the pill.

EFFECTIVENESS OF ORAL CONTRACEPTIVES

EFFC (TWRESS OF OVALIA CONTINCEPTIVES Oral contraceptises or "arth control pile" of the pile" are used to prevent pregnancy are taken correctly, the chance of becomes pregnants is less than 3% () pregnancy per used to use of the chance of becomes pregnants is less than 3% () pregnancy per used to use when used perfectly, whole missions gan ypile. Trypical faluer rates are actually 3% per year. The chance of becoming pregnant increases with each missed pil during a mestrual cycle. 100

In comparison, typical failure rates for other methods of birth control during the first year of use are as follows:

Male sterilization: <1%	
Cervical Cap: 20 to 40%	
Condom alone (male): 14%	
Condom alone (female): 21%	
Periodic abstinence: 25%	
Withdrawal: 19% .	
No method: 85%	
	Cervical Cap: 20 to 40% Condom alone (male): 14% Condom alone (female): 21% Periodic abstimecce: 25% Wthdrawal: 19%.

WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES

Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite mar in women over 35 years of age. Women who use oral contraceptives strongly advised not to smoke.

Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregr

u should also not use the pill if you have e any of the fo na cor

- A history of heart attack or stroke
 A history of beart attack or stroke
 Biod cots in the legs (thrombophebits), lungs (pulmonary embolism), or eyes
 A history of bodd clos in the deep veins of your legs
 Chest pain (angina pactros)
 Chest pain (angina pactros)
 Unervisited the blending (until a diagnosis is reached by your doctor)
 Velowing of the whites of the eyes or of the sikn (jaundce) during preguancy or during previous or of the pain
 Liver tumor (being or cancerous)
 Liver tumor (being or cancerous)
 Liver tumor (bassibury). This may increase levels of the leve enzyme "abnie animotizand" (Lis).

Tal your healthcare provider If you have ever had any of these conditions. Your healthcare provider can recommend as addre mothod of bith control. OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES Tal your healthcare provider If you have: • Breast nodules, fibrocystic disease of the breast, an abnormal breast x-ray or mammogram.

mammogram Diabetes Elevated cholesterol or triglycerides High blod pressure Migraine or other headaches or epiepsy Depression Gabibuider, heart or kidney disease History of scanty or irregular menstrual periods

Women with any of these conditions should be checked often by their healthcare provider if they choose to use oral contraceptives. Also, be sure to inform your doctor or healthcare provider if you smoke or are on any medications.

RISKS OF TAKING ORAL CONTRACEPTIVES

RISK OF TANING ORAL CONTRACEPTIVE 1. Risk of Developing Block OCtol Blood closts and blockage of blood vessels are the most serious side effects of taking and contraceptives; in particular, a clost in the legs cause thrombophetis, and a clot that travels to the lungs cau cause a sudden blocking of the vessel carrying blood to lungs. Rarely, to los cicur in the blood vessels of the legs and may cause blindness. If you take and contraceptives and need elective surgery, need to stay in bed for a problong dimess, or have recently deviced a bably, you may be at risk of developing blood clost. You should consult your doctor about stopping or is contraceptives three on vesses bloor surgery and not taking or all contraceptives for two weeks after develop of a bably. It is advisable to wait for at heast four weeks after delevery if you are the stateflenging, you and blackeflenging, you should wut mill you have ended leng. *INECUTIONSI*. 2. head that class and structs

Heart Attacks and Strokes 2.

2. Heart Attacks and strokes profactortraceptine may increase the tendency to develop strokes (stoppinge of rupture of a contraceptine may increase the tendency to develop strokes (stoppinge of vesses) in the heart). Any of these conditions can cause death or disability. Smoking oracity increases the possibility of suffreing heart attacks and strokes. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and diving of heart takese.

 ueveoping and dying of heart disease.
 Galibladder Disease
 Oral contraceptive users probably have a greater risk than nonusers of having galibladder disease, although this risk may be related to pills containing high doses of estrogens. roge

Liver Tumors

are cases, and contracted with a set of a case behing had dangerous live turners. These beings have turners can regulare and case fatal informal blending in addition, a possible but not definite association has been found with the pil and liver cancers in two studies in which a few women who developed these very rare cancers were found to have use oral contraceptives for long periods. However, liver cancers are textremely rare. The chance of developing liver cancer form using the pills were marker. Risk of Cancer 5

It is not known if hormonal birth control pills cause breast cancer. Some studies, but not al, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use.

If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones.

Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives.

ESTIMATED RISK OF DEATH FROM A BIRTH CONTROL METHOD OR PREGNANCY

All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to disability or death. An estimate of the number of deaths associated with different methods of birth control and pregnancy has been calculated and is shown in the following table.

ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FEBTULITY PER 100,000 NONSTERILE

Method of control and outcome	15 to 19	20 to 24	25 to 29	30 to 34	35 to 39	40 to 44
No fertility control methods	7.0	7.4	9.1	14.8	25.7	28.2
Oral contraceptives non-smoker	0.3	0.5	0.9	1.9	13.8	31.6
Oral contraceptives smokers	2.2	3.4	6.6	13.5	51.1	117.2
IUD	0.8	0.8	1.0	1.0	1.4	1.4
Condom	1.1	1.6	0.7	0.2	0.3	0.4
Diaphragm/spermicide	1.9	1.2	1.2	1.3	2.2	2.8
Periodic abstinence	2.5	1.6	1.6	1.7	2.9	3.6

In the above table, the risk of death from any birth control method is less than the risk of childhirth, except for oral contraceptive users over the age of 35 who smoke and pl users over the age of 40 even if they do not smoke. It can be sen in the table that for women aged 15 to 39, the risk of death was highest with pregnancy (7 to 26 deaths ye always), which we have that a solution of the second table that for contract the second table that the regnancy of the table table table table tables and the second table tables and the second table tables and the second tables and tables tables and tables tables tables and tables tables tables and tables ta

Tak associates which pregimeny set 200,000 which is the grig global, The associates which pregimes are set of the set of

WARNING SIGNALS

WARNING SIGNALS If any of these adverse effects occur while you are taking oral contraceptives, cal your doctor immediately: Sharp chets pain, coughing of blood, or sudden shortness of breath (indicating a possible cbr in the lung) Consulting creating in an passible cbr. In the log) Consulting creating in an imaviewer in the chest (indicating a possible heart attack) Sudden severe headache or vomiting, diszibress or fanting, distruthances of vision or speech, weakness, or numbers an arm or leg (indicating a possible torke) in the chest Sudden partial or compilet biss of vision (indicating a possible torke) Sudden partial or compilet biss of vision (indicating a possible cold in the reset). Sudden partial or compilet biss of vision (indicating a possible cold in the reset) Sudden partial or compilet biss of vision (indicating a possible cold in the preset user pain or tenderness in the stomach area (indicating a possible yoptured liver tumor)

- Diffucility is been readen to a sub-control of the second second

SIDE EFFECTS OF ORAL CONTRACEPTIVES

Side EFFECTS OF ORAL CONTRACEPTIVES
1. Voginal Bleeding
Irregular vaginal bleeding or spotting may occur while you are taking the pBi. Irregular bleeding may vary from slipts tating between mestrula periods to breakthrough bleeding which is a flow much like a regular peedid. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pBi for some time. Such bleeding may be temporary and usually does not indicate serious problems. It is important to continue taking your pBis on schedule. If the indicate serious problems. It is important to continue taking your pBis on schedule. If the doctor or healthcare provider.

2. Contact Lenses

f you war contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or healthcare provider.
 Fluid Retention

Oral contraceptives may cause edema (fluid retention) with swelling of the fingers or ankles and may rake your blood pressure. If you experience fluid retention, contact your doctor or heathcare provider.

Melasma

A spotty darkening of the skin is possible, particularly of the face. Other Side Effects

Other side effects may include change in appetite, headache, nervousness, depress dizziness, loss of scalp hair, rash, and vaginal infections.

If any of these side effects bother you, call your doctor or healthcare provider

GENERAL PRECAUTIONS

Missed Periods and Use of Oral Contraceptives Before or During Early Pregnancy 1. Missed Periods and Use of Oral Contraceptives Before or During Early There may be times when you may not remistrutar equipity after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrutal period, continue taking your pills for the net cycle but be sure to inform your and missed a menstrula period, of I' you missed two consecutive menstrula periods, you may be pergenant. Check with your healthcare provider minelitatey to determine whether you are pregnant. Du not continue to take or al contraceptives unity you are use you are not pregnant. Use on them to use another method of contraceptive.

see is no conclusive evidence that oral contraceptive use is associated with an ensem beth detects, when taken insubvertingly during any prepanacy. Previously, studies had reported that oral contraceptives might be associated with birth test, but these studies have not been confirmed. Never theses, or al contraceptive studies and the studies of the studies of the studies of the studies scribed by your doctor. You should check with your doctor about reks to your on child of any medication taked outing prepanacy. increas few stu defects or any prescri

While Breastfeeding

2. While Breastfeeding if you are breastfeeding, consult your doctor before starting orai contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (quancies and breast entryment. In addition, or al contraceptives may decrease the amount and quality of your milk. If method of contraceptives may decrease the amount and quality of your milk. If method of contraceptives in partial protection decreases significantly as you breastleed for longe period time. You should consider starting oral contraceptives only after you have warned your child completely.
3. Laborator Tests
If you are scheduled for any laboratory tests, tell your doctor you are tailing bith control pible. Center those the sime you be affected by bith control pible.

Drug Interactions

4. Drug Interactions Certain drugs may heract with birth control pills to make them less effective in preventing pregnancy or cause an increase in breaktmough bleeding. Such drugs benchabribali, carbanazopen, and physion (blann's less one brand of this drug); troglitzonce, phenybutazone, and possby certain ambibits. You may need to use additional contraception when you lake drugs which can make oral contraceptives less

Birth control pills interact with certain drugs. These drugs include acetaminophen, clofibric acid, cyclosporine, morphine, prednisolone, salicylic acid, temazepam, and theophyline. You should tell your doctor if you are taking any of these medications

 This product (like all oral contraceptives) is intended to prevent preg such as Chiamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis. ncy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted infections

INSTRUCTIONS TO PATIENT

Blister

usacer The Bisovi ef 1.5/30 bister has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing on the bister above the first row of tablets.

Each blister contains 21 pink tablets and 7 brown tablets.

Each pink tablet contains 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol Each **brown** tablet contains 75 mg ferrous fumarate, and is intended to help you remember to take the tablets correctly. These brown tablets are not intended to have any health benefit.

DIRECTIONS

To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the bister. Do not press on the tablet with your thumbnai, fingernail, or any other sharp object.

HOW TO TAKE THE PILL

Г IMPORTANT POINTS TO REMEMBER

BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS:

· Before you start taking your pills

Anytime you are not sure what to do

Anytime you are not sure what to do
 THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pile you could get prepand.
 This includes starting the pack late. The more pile you miss, the more likely you are to get prepand.

ger preginant. 3. MANY WONEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS. If you do have spotting or light bleeding or feel sick to your stomach, do not stopt taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic.

4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach.

Crown and viter a flux Sick to your Stomach. 5. If YOU HAVE YOUMTIKO RD RURAWHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your brith control jols may not work as well use a back-up brith control method (such as condoms or foam) until you check with your doctor or clinic. 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PULL tak to your doctor or clinic about how to make planking easier or about using another method of birth control.

7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic.

BEFORE YOU START TAKING YOUR PILLS

DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day.


LOOK AT YOUR PILL PACK TO SEE IF IT HAS 28 PILLS: The <u>28-pill pack</u> has 21 "active" pink pills (with hormones) to take for 3 weeks followed by 1 week of reminder brown pills (without hormones).

ALSO FIND:

Г

where on the pack to start taking pills.

- in what order to take the pills (follow the arrows), and, the week numbers as shown in the following picture:



TAKE PILLS IN THIS DIRECTION FROM LEFT TO RIGHT FACH WEF

For use of day labels, see WHEN TO START THE FIRST PACK OF PILLS below

BE SURE YOU HAVE READY AT ALL TIMES: DE SURE IOU INVERSION AT ALL TIMES.
 ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills.
 AN EXTRA, FULL PILL PACK.

WHEN TO START THE FIRST PACK OF PILLS

You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember.

DAY-1 START:

- Y-1 START: Pick the day label strip that starts with the first day of your period. (This is the day you start labeleding or sporting, even if it is almost midnight when the bleeding begins.):
- begins.): 2. Place the day label strip on the blister over the area that has the days of the week (starting with Sunday) printed on the blister. 3. Take the first "active" pink pill of the first pack during the <u>first 24 hours of your</u> coded
- LETLAG. 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period.

- SUNDAY START: 1. Take the first "active" pink pill of the first pack on the <u>Sunday after your period starts</u> even if you are still bleeding. If your period begins on Sunday, start the pack that range day.
- same day.
 2. <u>Use another method of birth control</u> as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control.

WHAT TO DO DURING THE MONTH Г

1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea).

sck to your stomach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS:

28 pills: Start the next pack on the day after your last "reminder" pill. Do not wait any days between packs. WHAT TO DO IF YOU MISS PILLS

Г

If you MISS 1 pink "active" pill:

. 1. Take it as soon as you remember. Take the next pil at your regular time. This m you may take 2 pills in 1 day.

you may use 2 pin in 1 uay. 2. You do not need to use a back-up bith control method if you have sex if you MISS 2 pink "active" pils in a row in WEEK 1 OR WEEK 2 of your p 1. Take 2 pils on the day you remember and 2 pils the next day. 2. Then take 1 pil a day until you finish the pack.

You COULD GET PREGNANT if you have sex in the <u>7 days</u> after you miss pills. You
MUST use another birth control method (such as condoms or foam) as a back-up

method of birth control until you have taken a pink "active" pill every day for 7 days If you MISS 2 pink "active" pils in a row in THE 3rd WEEK:

If you MIBS 2 pink rative pils in a row in the and where: 1 if you are a Support Starter: THROW OUT the rest of the pil pack and start a new pack that same day. If you are a Support Starter: Keep taking 1 pil every day unti-Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pils that same day.:

You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant 3. You COULD GET PREGNANT if you have sex in the <u>7 days</u> after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control nutl you have taken a pink "active" pill every day for 7 days.

If you MISS 3 OR MORE pink "active" pills in a row (during the first 3 weeks)

If you are a Day-1 Starter: THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter:

Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant

3. You COULD GET PREGNANT if you have sex in the <u>7 days</u> after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up method of birth control until you have taken a pink "active" pill every day for 7 days.

A REMINDER FOR THOSE ON 28-DAY PACKS: IF YOU FORGET ANY OF THE 7 BROWN "REMINDER" PILLS IN WEEK 4:

THROW AWAY THE PILLS YOU MISSED.

KEEP TAKING 1 PILL EACH DAY UNTIL THE PACK IS EMPTY. YOU DO NOT NEED A BACK-UP METHOD.

FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED:

Use a BACK-UP METHOD anytime you have sex.

KEEP TAKING ONE PINK "ACTIVE" PILL EACH DAY until you can reach your doctor or clinic

PREGNANCY DUE TO PILL FAILURE

The incidence of pill failure resulting in pregnancy is approximately 1% (i.e., one pregnancy per 100 women per year) if taken every day as directed, but more typical failure rates are about 3%. If failure does occur: the risk to the fetus is minimal.

PREGNANCY AFTER STOPPING THE PILL

There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had irregular menstruial cycles before you used oral contraceptives. It may be advisable to postpone conception unit you begin menstruating regularly once you have stopped taking the pill and desire pregnancy. There does not appear to be any increase in birth defects in newborn babies when pregnancy occurs soon after stopping the pill.

OVERDOSAGE

Serious Bieffects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your health care provider or pharmacist.

pharmack: **OTHER INFORMATION** Your healthcare provider will take a medical and family history and examine you before prescribing on a contrace pitws. The physical examination may be delayed to another time I you request I and your healthcare provider beleves that I is a good medical precloudy in this kaflet. Be sure to keep all apportments with your healthcare provider previously in this kaflet. Be sure to keep all apportments with your healthcare provider contracepible use. The sure there are early apportments with your healthcare provider contracepible use. And there are early apportments with your healthcare provider contracepible use. And there are early apportments with your healthcare provider of most inter drug for any condition other than the one for which I was prescribed.

Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control plis.

HEALTH BENEFITS FROM ORAL CONTRACEPTIVES

HEALTH BENEFITS FROM ORAL CONTRACEPTIVES In addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are: Blood flow during mestruation may be lighter and less iron may be list. Therefore, anema due to ino deficiency is list likely to occur Pain or other symptoms during mestruation may be encountered less frequently Pain or other symptoms during mestruation may be encountered less frequently Homomore that predictor it may too hereast mayor. The frequently A courte period in the out benefits that may be interest that Oral contraceptive use may provide some protection against developing two forms of cancer: ancer of the overies and cancer of the ining of the uterus.

If you want more information about birth control plis, ask your doctor or pharmacist. They have a more technical leaflet called the "Physician Insert", which you may wish to read.

Remembering to take tablets according to schedule is stressed because of its importance in providing you the greatest degree of protection.

MISSED MENSTRUAL PERIODS FOR BOTH DOSAGE REGIMENS

MISSED MENSTRUAL PERIODS FOR BOTH DOSAGE REGIMENS At times there may be no menstrual period after a cycle of plis. Therefore, if you miss one mestrual period but have taken the plis exactly so you were supposed to, continue as usual into the next cycle. If you have not taken the plis correctly and miss a mission of the period of the plis search as you were supposed to, continue and the provide provide the plis search as you were supposed to, continue and the plice plice of the plice search and the plice correctly and miss a mission of the plice of the plice search and the plice search and the plice determined whether or not you are pregnant. Although there does not appear to be any increase in birth directs in needborn bable. If you become pregnant while using orall contraceptives, you should discuss the stuation with your doctor or healthcare provider.

Periodic Examination:

Your doctor or health care provider will take a complete medical and family history before prescribing oral contraceptives. At that time and about once a year thereafter, he or she will generally examine your blood pressure, breasts, abdomen, and pelvic organs (including a Papanicolaus smear, i.e., test for cancer).

Keep this and all drugs out of the reach of children. Rx only

Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F). [see USP Controlled Room Temperature].

ID#: 274720

Blister Pack: 28

Blsovi[™] Fe 1.5/30 is a trademark of Lupin Pharmaceuticals, Inc. The other brands listed are trademarks of their respective owners and are not trademarks of Lupin Pharmaceuticals, Inc. The makers of these brands are not affiliated with and do not endorse Lupin Pharmaceuticals, Inc. or its products.

Distributed by: Lupin Pharmaceuticals, Inc.

Lupin Pharmaceuticals, Baltimore, Maryland 21202 United States Manufactured by: Lupin Limited Pithampur (M.P.) - 454 775 Revised: November 2023

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Blisovi" Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets*)

1.5 mg/0.03 mg NDC: 68180-866-71

Blister Pack: 28 Tablets Desc: Blisovi Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets)

1.5 mg/0.03 mg NDC: 68180-866-71

Tablets



Blisovi''' Fe 1.5/30

Insort re 1.5/30 (norethindrone acteate and ethinyl estradiol tablets USP and ferrous fumarate tablets*) 1.5 mg/0.03 mg NDC: 6810-886-71 Pouch Pack: 1 Blister of 28 Tablets Desc: Blsovi Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets) 1.5 mg/0.03 mg NDC: 68180-866-71

Blister of 28 Tablets



Bilsovi" Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets*) 1.5 mg/0.03 mg NDC: 6810-6673 Carton: 3 Bister of 28 Tablets Each Desc: Bisovif Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets) 1.5 mg/0.3 mg NDC: 68180-866-73 Carton: 3 Bister



BLISOVI FE 1.5/30

Product Info	rmation						
		ESCRIPTION DRUG	Item	Code (S	ource)	NDC:68	180-866
Packaging							
# Item Code	Pa	ackage Description		Mark	eting Start Date	Marke	ting End
1 NDC:68180-866-				11/07/20			
1	1 in 1 POUCH						
1	1 in 1 BLISTER Product	t PACK; Type 0: Not a Co	mbination				
Quantity of P							
Part 1	Package	Quantity	21	Tota	l Product Qu	antity	
Part 2			7				
Part 1 of 2							
BLISOVI FE	1.5/30						
norethindrone a	acetate and e	ethinyl estradiol tabl	et .				
Product Info							
Route of Admin	istration	ORAL					
Active Ingred	lient/Active	Moiety					
ETHINKI EETBAD	OL (1801, 4327	redient Name 2T571U) (ETHINYL ESTR	10101		Basis of S		0.03 mg
NORETHINDRONE	ACETATE (UN	IL 9544LIC70J) (NORETH	INDROINE -		NORETHINDRO		1.5 mg
UNI: (18F433X4S)					ACETATE		
Inactive Ingre	adiont						
mactive ingre		Ingredient Name				Str	ength
ACACIA (UNII: SCS-	403N260)						
LACTOSE MONOP	YDRATE (UNI	EWQ57Q8I5X)					
MAGNESIUM STEA	ARATE (UNI: 70	0097M6(30) Sin					
SUCROSE (UNI: C	151H8M554)	*p					
TALC (UNI: 75EV7)	(4R1U)						
Product Char							
					Score		10 SCOTE
Color Shape		lat face beveled edged)			Score Size		no score šmm
Color Shape Flavor							šmm
Color Shape Flavor					Size		šmm
Color Shape Flavor Contains	PINK (Pink) RDUND (round;1	lat face beveled edged)			Size		šmm
Color Shape Flavor Contains Marketing	PINK (Pink) ROUND (round;1	lat face beveled edged) tion	10graph		Size Imprint Code		imm JJ;K24
Color Shape Flavor Contains Marketing Category	PINK (Pink) ROUND (round;1	lat face beveled edged) tion cition Number or Mo Citation	1ograph		Size Imprint Code ceting Start Date		imm JJ;K24
Color Shape Flavor Contains Marketing Category	PINK (Pink) RDUND (round;1 Informat Applica	lat face beveled edged) tion cition Number or Mo Citation	nograph	Mari	Size Imprint Code ceting Start Date		imm JJ;K24
Color Shape Flavor Contains Marketing Marketing Category MDA	Informal Applica AndA20151	lat face beveled edged) tion cition Number or Mo Citation	tograph	Mari	Size Imprint Code ceting Start Date		imm JJ;K24
Color Shape Flavor Contains Marketing Marketing Category ANDA Part 2 of 2	Informat Applica ANDA2015	lat face beveled edged) tion cition Number or Mo Citation	sograph	Mari	Size Imprint Code ceting Start Date		imm JJ;K24
Color Shape Flavor Contains Marketing Marketing Category ANDA Part 2 of 2 BLISOVI FE	Informat Applica ANDA2015	lat face beveled edged) tion cition Number or Mo Citation	tograph	Mari	Size Imprint Code ceting Start Date		imm JJ;K24
Color Shape Flavor Contains Marketing Marketing Category ANDA Part 2 of 2 BLISOVI FE	Informat Applica ANDA2015	lat face beveled edged) tion cition Number or Mo Citation	iograph	Mari	Size Imprint Code ceting Start Date		imm JJ;K24
Color Shape Flavor Contains Marketing Category ANDA Part 2 of 2 BLISOVI FE inert tablet	Informat Applica Applica Antox20151	lat face beveled edged) tion cition Number or Mo Citation	sograph	Mari	Size Imprint Code ceting Start Date		imm JJ;K24
Color Shape i Flavor Contains Marketing Category ANDA Part 2 of 2 BLISOVI FE inert tablet Product Infor	Paec (Pink) NOUND (round) Informat Applica ANDA20151 E 1.5/30	Let face beveled edged) Lion Lion Number or Mo Citation 15	sograph	Mari	Size Imprint Code ceting Start Date		imm JJ;K24
Color Shape i Flavor Contains Marketing Category ANDA Part 2 of 2 BLISOVI FE inert tablet Product Infor	Paec (Pink) NOUND (round) Informat Applica ANDA20151 E 1.5/30	Let face beveled edged) Lion Lion Number or Mo Citation 15	sograph	Mari	Size Imprint Code ceting Start Date		imm JJ;K24
Color Color Pavor Contains Pavor Contains Marketing Category ARDA Part 2 of 2 BLISOVI FE Inert tablet Product Infor Route of Admin	Informal Applice Applice Antoxeoisi E 1.5/30	Lat face betweld edged) tion tion Number or Mo Citation 55	iograph	Mari	Size Imprint Code ceting Start Date		imm JJ;K24
Color I Shape Flavor Contains Marketing Marketing Category ANDA Part 2 of 2 BLISOVI FE inert tablet Product Infon Route of Admini Inactive Ingr	PREC (PHR) ADDURD (round: Applica Applica AMDA20151 E 1.5/30 rmation istration adjents	Lat face beweld edged) tion tion Number or Mo Citation 5 0044 Ingredient Nat		Mari	Size Imprint Code ceting Start Date	Mark	imm JJ;K24
Color Color Flavor Marketing Category ARDA Part 2 of 2 BLISOVI FF Inerttablet Product Infor Route of Admin Inactive Ingr Celluloss, micr	Informal Applica Applica ANDADISI E 1.5/30 rmation istration edients ROCRYSTALLIA	to face breviet edged)		Mari	Size Imprint Code ceting Start Date	Mark	ating End
Color Flavor Flavor Contains Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Product Infor Route of Admin Inactive Ingre CelluloSe, Mick	Informal ROUND (round; Applica Applica AbbA20151 E 1.5/30 mation istration edients ROCRYSTALLI ROCRYSTALLI ROCRYSTALLI AND ROLANS	to face brevield edged) tion tion Obta Obta Obta Obta Obta Obta Obta Obta		Mari	Size Imprint Code ceting Start Date	Mark	ating End
Color P Flavor Flavor Contains Marketing Marketing Category ANDA Part 2 of 2 BLISOVI FE Inert tablet Product Infor Route of Admin Inactive Ingre Category Category Category Category Category Category Part 2 of 2 BLISOVI FE Product Infor Route of Admin Inactive Ingre	Informal ROUND (round) Applica Applica AntoAcotsi E 1.5/30 rmation histration edients ROCRYSTALLI ARE (UNE POL- ANTE (UNE POL- ANTE (UNE POL- ANTE (UNE POL- ANTE (UNE POL- ANTE (UNE POL-	to face brevield edged) tion tion Obta Obta Obta Obta Obta Obta Obta Obta	ne	Mari	Size Imprint Code ceting Start Date	Mark	ating End
Color P Flavor Flavor Contains Marketing Marketing Category ANDA Part 2 of 2 BLISOVI FE Inert tablet Product Infor Route of Admin Inactive Ingre Category Category Category Category Category Category Part 2 of 2 BLISOVI FE Product Infor Route of Admin Inactive Ingre	Informal ROUND (round) Applica Applica AntoAcotsi E 1.5/30 rmation histration edients ROCRYSTALLI ARE (UNE POL- ANTE (UNE POL- ANTE (UNE POL- ANTE (UNE POL- ANTE (UNE POL- ANTE (UNE POL-	to face breviet edged) tion tion to face breviet or Moc Cost to Dotate D	ne	Mari	Size Imprint Code ceting Start Date	Mark	ating End
Color Contains Flavor Contains Flavor Contains Marketing Marketing Marketing Nava Part 2 of 2 BILSOVI FF BILSOVI FF Route of Admin Inactive Ingre CelluloSE, Mich Ferrous Funda Machesium Stro Otopole Studies Success (unit contains)	Informal Application Application Informati	ter face brokel edged) tion tion Cleater Cleater Cleater Days	ne	Mari	Size Imprint Code ceting Start Date	Mark	ating End
Color Shape Flavor Contains Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Part 2 of 2 BLISOVI FE BLISOVI FE Product Infor Reute of Admin Inactive Ingro Cellulos, Mic Francus FUMA Marketing Transus FUMA South States South Sta	Informat Application Applicati	Lion Nuclear of the second sec	ne	Mari	Size	Mark	Some
Color Shape Flavor Contains Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Marketing Product Infor Reute of Admin Inactive Inger Cellbiose, Junc South Status Str. South Status Str. South Status Str. South Status Str. South Status Str. South Status Str.	Informat Application Applicati	Lion Nuclear of the second sec	ne	Mar1	Size	Mark	sme butter End Strength
Color Shape Flavor Flavor Contains Marketing Marketing Marketing Marketing Marketing Marketing Marketing Part 2 of 2 BLISOVI FF Inert tablet Product Infor Reute of Admin Inactive Ingr Cellulos, MC Fanous Flava	Informat Application Applicati	Lion Nuclear of the second sec	ne	Mar1	Size	Mark	In the second se
Color Shape Flavor Flavor Contains Marketing Marketing Marketing Marketing Marketing Marketing Marketing Part 2 of 2 BLISOVI FF Inert tablet Product Infor Reute of Admin Inactive Ingr Cellulos, MC Fanous Flava	Informat Application Applicati	Lion Nuclear of the second sec	ne	Mar1	Size	Mark	sme butter End Strength
Color Shape Flavor Contains Marketing Marketing Marketing Category ADDA Part 2 of 2 BLISOVI FF Iner tablet Product Infor Route of Admin Inactive Ingor Category Product Infor Route State State State Product Infor Route States States	Information Applic	Lion Number or New Control States of the States of the Control Sta	ne	Mar1	Size	Mark	sme butter End
Color Shape Flavor Flavor Category Marketing Marketing Marketing Marketing Marketing Product Info Route of Admin Inactive Ingre Cellulo54, sec Francus rollan Social States Social States Product Char Color Flavor Flavor Flavor Flavor Shape Flavor Flavor Shape Flavor Flavor Flavor Shape Flavor Flavor Flavor Shape Flavor Flav	Information	ter face treveled experi tion tion Number of Non- Solution Number of Non- Number of Number o	ne 854350242)	Marti	size mmprint Code	Mark	Inne UMP24
Color Shape of Floor of Floor of Floor of Floor of Floor of Contains Marketing Marketing Marketing Part 2 of 2 BLISOVI Floor BLISOVI Floor Floor tablet Product Infor Reute of Admin BLISOVI Floor Status of Admin Product Infor Reute of Admin Product Infor Reute of Admin Product Infor Reute of Admin Celluloss, sec Product Char Contains (Contains) Provent Char Contains (Contains)	Informal Figure 1 Fig	Lion Number or New York of Control (1997)	ne 854350242)	Mari	size mpyrint Code coting Start Dig Start Start size	Mark	Inne UMP24
Color Shape of Floor of Floor of Floor of Floor of Floor of Contains Marketing Marketing Marketing Part 2 of 2 BLISOVI Floor BLISOVI Floor Floor tablet Product Infor Reute of Admin BLISOVI Floor Status of Admin Product Infor Reute of Admin Product Infor Reute of Admin Product Infor Reute of Admin Celluloss, sec Product Char Contains (Contains) Provent Char Contains (Contains)	Information	Lion Number or New York of Control (1997)	ne 854350242)	Marti	size mpyrint Code coting Start Dig Start Start size	Mark	Inne UUS24
Color Shape I favor From I From I From I From I Marketing Marketing Route of Admin BLISOV IF Route of Admin Inactive Ingre Color France Ingre Collumose, Marketing Route of Admin Marketing Route of Admin Frances I Product Infor Frances I Product I	Informal Applications Accession and application Accession accessio	tion number of the second seco	ne 854350242)	Mari	size mpyrint Code coting Start Dig Start Start size	Mark	Inne UUS24
Color Shape Flover Castains Marketing Marketing Marketing BallSOVI Flover Product Infor Route of Admin Inactive Ingro CellulOSE, Mic Product Infor Route of Admin Inactive Ingro CellulOSE, Mic Product Char Color Shape Friver Contains Marketing Marketing Marketing	Information Several Regime	ter face travited edge(d) tion Number or Mon Content of the Content of the Cont	ne 854350242)	Mart 11/07/2	size manipulation size size size size size size size size	Mark	sting End
Color Shape in Prover in P	Information Sector Sect	Lion Number of North States and S	ne 856j502A2) 10graph	Marti	size may be a size of the size	Mark	sting End
Color Shape Filvor Castains Marketing Marketing Castagry Mon Part 2 of 2 BILSOVI Fil net tablet Product Infor Route of Admin BILSOVI Fil Route of Admin Inactive Ingro Castagry Product Char Color Shape Filvor Contains Marketing Marketing Marketing	Information Several Regime	Lion Number of North States and S	ne 854350242)	Marti	size may be a size of the size	Mark	sting End

Labeler - Lupin Pharmaceuticals, Inc. (089153071)

Registrant - LUPIN LIMITED (675923163)

Establishment
Name Address DiPE Business Operations
(5052230) AM MARIFICTURE(5830.546), MMARIFICTURE(5830.546), MMARIFICTURE(5